Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest H5N1 clinical trials Stories

2009-09-15 14:22:00

LYON, France and SWIFTWATER, Pa., Sept. 15 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine. The U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine is an inactivated influenza virus vaccine indicated for active...

2009-09-14 10:16:18

U.S. officials said they are encouraged by the progress of various clinical trials of H1N1 influenza vaccines. The early data from these trials indicate the H1N1 influenza vaccines are well tolerated and induce a strong immune response in most healthy adults when administered in a single unadjuvanted 15-microgram dose, said a statement by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. NIAID is also conducting clinical trials of H1N1...

2009-09-09 12:43:05

Researchers in New York say they have identified two protein fragments that could be developed into a new anthrax vaccine. Scientists from Yeshiva University's Albert Einstein College of Medicine said their research suggests the protein fragments could lead to a vaccine with fewer side effects than the current vaccine. Our research was motivated by the fact that the current anthrax vaccine has significant limitations and there is great need for a better one, said postdoctoral fellow Nareen...

2009-09-08 09:00:00

SAN FRANCISCO, Sept. 8 /PRNewswire/ -- Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has been awarded a $2.8 million phase II Small Business Innovation Research grant from the National Institute of Allergy and Infectious Disease (National Institutes of Health) to support development of its first product, an orally-delivered vaccine for H5N1 Avian influenza. "We thank the NIH for funding the further safety and efficacy tests, which, along with our...

2009-09-08 05:00:00

BOZEMAN, Mont., Sept 8 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received...

2009-08-28 07:00:00

BEIJING, Aug. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the Beijing Public Health Bureau has selected Sinovac as one of the four manufacturers to supply Anflu(R), Sinovac's seasonal influenza vaccine, for the benefit of the citizens of Beijing. The Beijing Public Health Bureau completed the bidding process for the purchase of flu vaccines and corresponding services for 2009 on August 26, 2009....

71d3d98ae82ac4e5bbf0ee086d2b3fd21
2009-08-19 13:02:42

U.S. researchers said on Tuesday that tobacco plants might yield a cheap and easy-to-administer vaccine against a pesky stomach virus called norovirus, Reuters reported. They found that tobacco can produce a protein that can be used to make a nasal vaccine against norovirus, which causes diarrhea and vomiting, particularly in settings where many people share limited space. Charles Arntzen, a plant biologist at Arizona State University, told a news conference at a meeting of the American...

2009-08-19 10:18:48

The U.S. subsidiary of a British drug company is signing up volunteers for clinical trials of its swine flu vaccine, the company says. MedImmune plans to run two U.S. vaccine trials simultaneously, one on children ages 3 to 17 and another for adults 18-49, Washington Business Journal reported Wednesday. If everything works well, we are expected to have our first doses ready by the end of October, said Perla Copernik, a spokeswoman for MedImmune, a subsidiary of AstraZeneca PLC in London....

2009-08-18 07:30:00

BEIJING, Aug. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, announced today positive top-line results from the completed clinical trial for its internally-developed H1N1 vaccine. The clinical data unblinding conference was held in Beijing on the afternoon of August 17, 2009. Notably, Sinovac is the first company worldwide to complete clinical trials for the H1N1 vaccine. The analysis of the clinical trial results showed that...

32e3c723332fc59afd15c79fb96d7f6f1
2009-08-15 07:53:43

On Friday, GlaxoSmithKline PLC, the drugmaker of a new swine flu vaccine, said that it has started to test the vaccine in humans. Glaxo said it is planning 16 clinical trials of its swine flu vaccine in over 9,000 people in Europe and North America.  The company expects to see results in September from its first trial in Germany.  The data will be shared with drug regulators so they will be able to decide whether to license the vaccine or not. The U.S. and Europe both have...